trending Market Intelligence /marketintelligence/en/news-insights/trending/JnH05ulZamCtEl74mHpNAw2 content esgSubNav
In This List

US FDA approves Sanofi's Admelog insulin lispro injection for diabetes

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA approves Sanofi's Admelog insulin lispro injection for diabetes

The U.S. Food and Drug Administration approved Sanofi's 100 units/milliliters dose of Admelog.

Admelog is a rapid-acting insulin similar to Eli Lilly and Co.'s Humalog, another insulin lispro 100 units/mL, currently approved in the U.S.

The clinical development program of Admelog, or insulin lispro injection — a follow-on mealtime insulin — involved more than 1,000 adults with type 1 or type 2 diabetes.

Sanofi said Admelog will be available in both vials and the SoloStar pen.

In September, the U.S. regulator granted a tentative approval to Admelog.

Admelog was also granted marketing authorization as a biosimilar, under the name Insulin lispro Sanofi, by the European Commission in July.